Generic Vyzulta Availability
Last updated on Apr 10, 2025.
Vyzulta is a brand name of latanoprostene bunod ophthalmic, approved by the FDA in the following formulation(s):
VYZULTA (latanoprostene bunod - solution/drops;ophthalmic)
-
Manufacturer: BAUSCH AND LOMB
Approval date: November 2, 2017
Strength(s): 0.024% [RLD]
Is there a generic version of Vyzulta available?
No. There is currently no therapeutically equivalent version of Vyzulta available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vyzulta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Prostaglandin derivatives
Patent 7,273,946
Issued: September 25, 2007
Inventor(s): Ongini; Eninnio et al.
Assignee(s): Nicox S.A. (Valbonne, FR)Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
Patent expiration dates:
- October 3, 2025✓✓✓
- October 3, 2025
-
Prostaglandin derivatives
Patent 7,629,345
Issued: December 8, 2009
Inventor(s): Ongini; Ennio et al.
Assignee(s): Nicox S.A. (Sophia Antipolis, FR)Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
Patent expiration dates:
- January 5, 2025✓✓
- January 5, 2025
-
Prostaglandin derivatives
Patent 7,910,767
Issued: March 22, 2011
Inventor(s): Ongini; Ennio et al.
Assignee(s): Nicox S.A. (Sophia Antipolis Cedex, FR)Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
Patent expiration dates:
- January 5, 2025✓✓✓
- January 5, 2025
-
Prostaglandin derivatives
Patent 8,058,467
Issued: November 15, 2011
Inventor(s): Ongini; Ennio et al.
Assignee(s): Nicox S.A. (Sophia Antipolis-Valbonne, FR)Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
Patent expiration dates:
- February 21, 2029✓✓
- February 21, 2029
More about Vyzulta (latanoprostene bunod ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (12)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: ophthalmic glaucoma agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.